The months ahead will determine whether they will become turning points or missed opportunities. Cancer does not wait for GDP targets, and patients cannot wait for promises to turn into action ...

Alkane Resources Ltd (ASX:ALK, OTC:ALKEF) has identified a gold-bearing structural corridor beneath its Roswell deposit at the Tomingley Gold Operations in New South Wales, as deep drilling continues ...

Q4 2025 Earnings Call March 2, 2026 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

Morgan Stanley Technology, Media & Telecom Conference 2026 March 3, 2026 12:15 PM ESTCompany ParticipantsEric Lefkofsky ...

Orziloben granted Orphan Drug Designation in the U.S. and European UnionCompany expects to report topline results from Phase 2 study in Q3 2026AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V.

Allied Market Research published a report, titled, "Allergy Immunotherapy Market by Type (Subcutaneous Immunotherapy and ...

Partner Therapeutics announces positive data from post hoc analysis of eNRGy trial evaluating treatment beyond progression with zenocutuzumab in patients with advanced NRG1+ NSCLC Lexington, ...

(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...

Orziloben granted Orphan Drug Designation in the U.S. and European Union Company expects to report topline results from Phase 2 study in Q3 2026 NorthSea Therapeutics B.V. ("NorthSea" or the "Company" ...

Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKRY) (‘Alkane’ or ‘the Company’) is pleased to announce the latest exploration results for the extension and infill drilling of the Kendal ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...